$117 Million is the total value of Birchview Capital, LP's 52 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BDSX | Buy | BIODESIX INC COM RST | $8,527,159 | +37.6% | 5,193,336 | +3.0% | 7.26% | +56.2% |
| PRTA | Buy | PROTHENA CORP PLC | $8,181,946 | -23.2% | 169,574 | +8.6% | 6.96% | -12.8% |
| BLUE | Buy | BLUEBIRD BIO INC | $1,383,808 | +68.8% | 455,200 | +82.7% | 1.18% | +91.5% |
| TXG | Buy | 10X GENOMICS INC | $866,250 | +29.3% | 21,000 | +75.0% | 0.74% | +46.8% |
| AXGN | Buy | AXOGEN INC | $865,000 | +136.9% | 173,000 | +332.5% | 0.74% | +168.6% |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $766,255 | +46.9% | 571,832 | +96.3% | 0.65% | +66.8% |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $733,080 | +19.3% | 82,000 | +105.0% | 0.62% | +35.4% |
| Buy | DOCGO INC | $692,900 | -32.8% | 130,000 | +18.2% | 0.59% | -23.7% | |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $684,720 | -37.4% | 18,000 | +50.0% | 0.58% | -28.8% |
| SILK | Buy | SILK ROAD MEDICAL INC | $618,997 | -4.7% | 41,294 | +106.5% | 0.53% | +8.2% |
| PGNY | Buy | PROGYNY INC | $612,360 | +73.0% | 18,000 | +100.0% | 0.52% | +96.6% |
| GOSS | Buy | GOSSAMER BIO INC | $174,128 | +46.4% | 209,088 | +111.0% | 0.15% | +66.3% |
| GTHX | Buy | G1 THERAPEUTICS INC | $172,800 | +73.5% | 120,000 | +200.0% | 0.15% | +96.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
| QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
| MASIMO CORP | 36 | Q3 2023 | 2.2% |
| PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
| XENCOR INC | 35 | Q3 2023 | 0.4% |
| NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
| CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
| BIOGEN INC | 31 | Q2 2022 | 3.1% |
| CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
| YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
| YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
| HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
| METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3/A | 2024-02-20 |
| 4/A | 2024-02-20 |
| SC 13G/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-04-07 |
| 4 | 2023-03-27 |
| 3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.